Innovent Biologics expands Phase 3 lung cancer trial globally
September 28, 2026 | 14:12
Biopharmaceutical manufacturer Innovent Biologics expanded its global Phase 3 MarsLight-11 clinical trial of candidate IBI363/TAK-928 to evaluate patients with immunotherapy-resistant non-squamous non-small cell lung cancer.
Mobile Version